Clinical Trials Logo

Clinical Trial Summary

Trauma is the leading cause of soft tissue loss of the heel. Children constitute the largest group of victims of such injuries. Spoke wheel injury, road traffic accident are common mode in the children. Oestern and Tscherne have classified soft tissue injuries into four grades from 0-4. The treatment of Grade 0 and 1 injuries is typical cleansing and application of a moist wound healing dressing. But further grades need surgical management with debridement and reconstruction. Grade III and IV can be reconstructed by using graft, flaps or various other techniques. . Skin grafting offers poor functional and cosmetic results, although it is commonly performed with good take rates. mesenchymal stem cells will be isolated from umbilical cord with informed consent from the mothers. This study will open a new avenue for the treatment of heel pad injury. . Since the use of stem cell (especially in Pakistan) is completely a new technique in the management of heel pad injury, it will provide insight for better management by accelerating the wound healing process.


Clinical Trial Description

Trauma is the leading cause of soft tissue loss of the heel. Children constitute the largest group of victims of such injuries. Spoke wheel injury, road traffic accident are common mode in the children. These injuries can range from simple minor abrasions, lacerations to crushing of heel. Injury to heel pad and flap has serious impact in day to day life, causing disability because it is the major weight bearing area and inherently lacks adequate soft tissue.

Management of injury of heel pad in children depends on severity and extent of soft tissue injury. Oestern and Tscherne have classified soft tissue injuries into four grades from 0-4. The treatment of Grade 0 and 1 injuries is typical cleansing and application of a moist wound healing dressing. But further grades need surgical management with debridement and reconstruction.

Grade III and IV can be reconstructed by using graft, flaps or various other techniques. Simple skin graft, lateral rotational skin flap, local muscle flaps, ingenious fasciocutaneous island flaps, cross-leg or cross foot flap, free tissue transfer and staged or distant jumped flaps are historically included in reconstructive ladder in repairing these soft tissue injuries. Generally, free flap reconstruction is the ultimate step of degloving wound coverage. Despite availability of various reconstructive techniques, covering of soft tissue loss of heel in traumatic events, remains a difficult and demanding procedure, especially when it is associated with fractures and complex wounds. Skin grafting offers poor functional and cosmetic results, although it is commonly performed with good take rates.

Stem cells are potential alternative to promote cutaneous wound healing because of its unique features like self-renewal and differentiation capacity. Mesenchymal stem cells are type of adult stem cells that reside in various tissues of the body. Besides, these cells are preferred for cell based therapies because they have immunomodulatory properties. These cells can be isolated from bone marrow, adipose tissue and human umbilical cord blood and tissue. Recently,umbilical cord derived mesenchymal stem cells have shown a tremendous potential for use in tissue engineering and regenerative medicine. Previous studies indicate that these mesenchymal stem cells can accelerate wound healing by enhanced proliferation and migration of human fibroblast, enhancing secretion of elastin, synthesizing collagen, angiogenesis and further maturing blood vessels present in wound site. Stem cell-based therapies will definitely be the major part of clinical medicine in next decade.

In the current study, mesenchymal stem cells will be isolated from umbilical cord with informed consent from the mothers. This study will open a new avenue for the treatment of heel pad injury. Considering the role of stem cells in wound healing, study has been designed to accelerate the wound healing process in children with heel pad injury. Since the use of stem cell (especially in Pakistan) is completely a new technique in the management of heel pad injury, it will provide insight for better management by accelerating the wound healing process, reducing the hospital stay and cost of treatment. Rationale of our study aims to compare outcome of heel pad injury managed with skin graft with infiltration of mesenchymal stem cell Versus management with skin graft only. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04219657
Study type Interventional
Source King Edward Medical University
Contact
Status Completed
Phase Phase 1
Start date October 29, 2016
Completion date December 22, 2019

See also
  Status Clinical Trial Phase
Completed NCT03641378 - Inpatient Palliative Care for Patients Undergoing Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT06155188 - Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia N/A
Recruiting NCT03562065 - Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord Phase 1/Phase 2
Completed NCT01468935 - Bone Marrow Cell Engraftment of the Uterus and Genetic Studies of Reproductive Functioning
Active, not recruiting NCT03938324 - Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions N/A
Not yet recruiting NCT03259217 - Clinical Application of Mesenchymal Stem Cells Seeded in Chitosan Scaffold for Diabetic Foot Ulcers Phase 1
Recruiting NCT01189786 - Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection N/A
Recruiting NCT04610359 - Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis Phase 1
Completed NCT05712148 - Spheroidal Mesenchymal Stem Cells in Retinitis Pigmentosa Phase 1/Phase 2
Recruiting NCT05515497 - BMT4me: Post-HSCT Medication Adherence mHealth App N/A
Completed NCT01984671 - Mobile Pain Coping Skills Training for Stem Cell Transplant Patients N/A
Not yet recruiting NCT06075927 - Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT Phase 1/Phase 2
Completed NCT03440775 - Digital Stories and Psychosocial Wellbeing in Stem Cell Transplant Patients N/A
Recruiting NCT02652052 - Hematopoietic Stem Cell Transplant Survivors Study N/A
Not yet recruiting NCT04922970 - Strength Training as Prevention and Treatment of Late Effects in Long-term Survivors of Pediatric HSCT. N/A
Completed NCT01092195 - Gardasil Vaccination in Post Stem Cell Transplant Patients Phase 1
Completed NCT04041219 - Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients Phase 4
Completed NCT00656058 - Montelukast to Treat Bronchiolitis Obliterans Phase 2
Recruiting NCT04375579 - Assessment of Elderly Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Completed NCT03859765 - In Person and mHealth Coping Skills Training for Symptom Management and Steps in Stem Cell Transplant Patients N/A